La cadena de opciones muestra datos clave de las opciones de acciones de Basel Medical Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Basel Medical Group..

Basel Medical Group (NASDAQ:BMGL) Bolsa, Cadena de Opciones

Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.

Basel Medical Group Ltd - ordinary shares

Basel Medical Group Ltd

News

NBIS

Nebius Invests In ClickHouse Series C To Unlock Value And Fuel AI Infrastructure Expansion

JBIO

Jade Biosciences Announced New Preclinical Data On JADE101, Its Anti-april Monoclonal Antibody Being Developed For The Treatment Of IgA Nephropathy (IgAN)

A. New proteoElute nanoflow nLC system features ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology
B. Introducing new generation of PepSep Advanced nLC columns to further improve chromatographic resolution, sensitivity and proteomics identifications
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263257&amp;newsitemid=20250602715993&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=17d2f94ec69b3f1e87b36b18a38df92a">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.

BRKR

Bruker Launches proteoElute nanoLC System, Advancing Ultra-Sensitive Proteomics

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439734-1&amp;h=3498642422&amp;u=https%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.">Trevi Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), is pleased to announce today positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54 mg BID and 27 mg BID dose groups achieved reductions from Baseline of 60.2% (p&lt;0.0001), 53.4% (p&lt;0.0001), and 47.9% (p&lt;0.01), respectively, compared to a placebo reduction from Baseline of 16.9%1.&nbsp;Statistically significant improvements were observed across&nbsp;secondary endpoints at Week 6 in the 108 mg BID and 54 mg BID dose groups.

TRVI

Trevi's Cough Drug Haduvio Shows Results in IPF Patients, Cutting Coughs by Over 60%

SCIEX And Evosep Sign Reseller Agreement To Expand Access To Standardized High-Throughput Proteomics For Pharma And Biotech

ZLAB

Zai Lab Limited Announced That Updated Data From An Ongoing, Global Phase 1A/1B Clinical Trial (NCT06179069) Evaluating Zocilurtatug Pelitecan, Or Zl-1310, The Company's Potential First-in-class, Delta-like Ligand (DLL3) Antibody-drug Conjugate (ADC) For Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Breakthrough Athena Ion Processor (AIP) delivers up to 35% more peptide and 20% more protein identifications for highest sensitivity proteomics
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263258&amp;newsitemid=20250602810313&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=7ec8a18c42acb3ef4e62e11c4e05f4ab">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced significant further advances in ultra-high sensitivity 4D-Proteomics&#x2122; with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF&#xAE; methods for key biological and clinical research problems with very low sample amounts.

Bruker Unveils New timsUltra AIP System With Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics And Metaproteomics

<a href="https://www.globenewswire.com/Tracker?data=NjIQv6kR4u-5jF8rBCclB-kIAf8osJ_pHaoa0lX7RsHypZRf7sCougOke6lBzNV3KWY9tnIpcTr7q8ZUi543FpymkEohGt4ySMmMbha9Bb4fYmKZP3GIGy-3mkx3xHqO">Outlook Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA&#x2122; (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA&#x2122; (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK.

OTLK

Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK

Guardant Health Announced That The Results Of The Phase III SERENA-6 Trial - Sponsored By Astrazeneca - Demonstrate The Clinical Value Of The Guardant360 Cdx Test In A Circulating Tumor DNA-guided Approach To Detect And Treat Emerging Resistance In 1St-line Therapy Ahead Of Radiological Disease Progression In Breast Cancer

–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials–
–Sebetralstat data demonstrated rapid relief and resolution of severe HAE attacks–
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54263164&amp;newsitemid=20250602100361&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b60b173695655aa779d872d069a426bb">KalVista Pharmaceuticals</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Deficiency &amp; Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida, from May 29–June 1, 2025.

KALV

KalVista Announces New Sebetralstat Data On HAE Attack Progression at Key Conferences

<ul>
<li>STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions</li>
<li>Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million</li>
<li>Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and retains an option to co-develop and co-promote in the U.S.</li>
</ul>

Biotech

Health Care

General

NRIX

Sanofi Has Exercised Its Option To Exclusively License Nurix Therapeutics' STAT6 Program, Including The Drug Development Candidate NX-3911, Nurix To Receive A $15M License Extension Fee From Sanofi Under Its 2019 Collaboration Agreement

Cyngn (the "Company" or "Cyngn") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced the launch of the Cyngn Dealer Portal, an online resource hub created to support its growing dealer network. The portal provides easy access to a comprehensive suite of Cyngn assets, including sales materials, detailed pricing information, and co-marketing resources. This new tool will allow dealers to effectively present Cyngn's autonomous solutions to their customers, increasing efficiency and facilitating faster sales cycles.
 &nbsp;

Cyngn Launches Dealer Portal to Speed Up Sales of Its Autonomous Vehicle Tech

<ul>
<li>– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms –</li>
<li>– Generally well-tolerated with low rates of adverse events and discontinuation –</li>
<li>– Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects –</li>
</ul>

RVPH

Reviva's Brilaroxazine Shows Broad, Durable Efficacy And Low Discontinuation In 1-Year RECOVER Phase 3 Extension Study

REGN

Regeneron Pharmaceutical Announced A Strategic In-licensing Agreement With Hansoh Pharmaceuticals Group Company Limited To Acquire Exclusive Clinical Development And Commercial Rights Outside Of The Chinese Mainland, Hong Kong And Macau For A Dual Glp-1/GIP Receptor Agonist Currently In Phase 3 Testing

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Buy and raises the price target from $85 to $90.

Price Target

Analyst Ratings

VRNA

HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $90

– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI&#xAE; (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
DUBLIN, June 2, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439097-1&amp;h=841886729&amp;u=https%3A%2F%2Fwww.alkermes.com%2F&amp;a=Alkermes+plc">Alkermes plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI&#xAE; (olanzapine and samidorphan) and ARISTADA&#xAE; (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers. The meetings included:
<ul>
<li>American Association of Psychiatric Pharmacists (AAPP) Annual Meeting, April 27-30, Salt Lake City</li>
<li>The Neuroscience Education Institute (NEI) Spring Congress, May 8-10, Philadelphia</li>
<li>The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 13-16, Montreal</li>
<li>American Psychiatric Association (APA), May 17-21, Los Angeles</li>
<li>American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 27-30, Scottsdale</li>
<li>Psych Congress Elevate, May 28-31, Las Vegas</li>
</ul>

ALKS

Alkermes Highlights LYBALVI And ARISTADA Data At Key Scientific Conferences

<ul>
<li>ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078).</li>
<li>ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full population of 3CS at 24 weeks (p=0.0209) and SNOT-22 score at 24 weeks (p=0.0101).</li>
<li>Additionally, in pooled data from ENLIGHTEN 2 and ENLIGHTEN 1 trials in 64 CRS patients with nasal polyps, LYR-210 demonstrated a consistent positive trend over 24 weeks in multiple key efficacy endpoints.</li>
<li>Lyra plans to review the totality of the dataset from the ENLIGHTEN trials to evaluate next steps for pursuing an indication in non-polyp patients, as well as to continue development of LYR-210 in patients with nasal polyps&nbsp;&nbsp;</li>
</ul>

LYRA

Lyra Therapeutics' ENLIGHTEN 2 Phase 3 Trial Of LYR-210 For Chronic Rhinosinusitis Met Its Primary Endpoint, With LYR-210 Demonstrating Statistically Significant Improvement Compared To Sham Control In A Composite Of The Three Cardinal Symptoms

Keybanc analyst Christopher Carril initiates coverage on Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Sector Weight rating.

Initiation

SHAK

Keybanc Initiates Coverage On Shake Shack with Sector Weight Rating

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4438958-1&amp;h=1951662543&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc.">Anixa Biosciences, Inc.</a> ("Anixa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. This novel vaccine, invented at Cleveland Clinic, is also being developed in partnership with Cleveland Clinic and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense (DoD).
The vaccine is designed to stimulate the immune system to target breast cancer before it can recur or develop. A total of 35 women have received the vaccine in the trial, including 26 in the triple-negative breast cancer ("TNBC") group, four in the prevention group, and five in the pembrolizumab group. These participants represent three distinct patient cohorts:
<ul>
<li>TNBC Group: Women who have completed treatment for triple-negative breast cancer, are currently cancer-free, and are at risk of recurrence.</li>
<li>Prevention Group: Women who are cancer-free but carry genetic mutations that place them at high risk of developing breast cancer and have elected to undergo preventative mastectomy to lower their risk.</li>
<li>Pembrolizumab (Keytruda) Group: Women who are receiving pembrolizumab in a post-operative setting. These women are receiving the vaccine concurrently with pembrolizumab.</li>
</ul>
The final patient visits are scheduled for August 2025. Once completed, the final study report will be submitted to the Department of Defense. A Clinical Study Report (CSR) will then be prepared for submission to the U.S. Food and Drug Administration. As part of the continued development process, the Investigational New Drug (IND) application will be transferred from Cleveland Clinic to Anixa.
Anixa and Cleveland Clinic plan to submit for presentation all trial data at a major upcoming scientific meeting.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "We are very encouraged by the data we are seeing from this trial. Preliminary results show that our breast cancer vaccine is well tolerated, with more than 70% of patients demonstrating protocol-defined immune responses. These encouraging findings are guiding our planning for Phase 2 trials, which will include discussions with the FDA, protocol development, manufacturing, and clinical site selection. While cancer vaccines have traditionally faced significant hurdles, our approach is aimed at a novel target that has not been previously explored in this context. We believe this could represent a new paradigm in immuno-oncology. The breast cancer market, particularly for triple-negative breast cancer and genetically high-risk populations, continues to face a major unmet need. Our vaccine may offer a unique, immunologic pathway for both prevention and treatment."

ANIX

Anixa Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Breast Cancer Vaccine

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Data continue to support planned initiation of pivotal study in mid-2025
Next-generation triplet combinations with atirmociclib (CDK4-selective) &amp; ribociclib ongoing
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Q0gTYYh0XNKiOiXKmI9gOsksgI8_wm3UouToi--Ehs1OVKagdDy56xsgmUueh0KPLXKLq3UXdZWqkn1HfkN7zoYBDDMyYEFAEORjJWyVHIQ=">Relay Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. The updated data have a median duration of follow-up of 12.5 months and remain consistent with data shared in December 2024. They show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600mg twice daily (BID) + fulvestrant. These data are being presented today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

RLAY

Relay Therapeutics Says Updated Interim Clinical Data For RLY-2608 Remain Consistent, Showing 10.3-Month Median PFS Overall And 11.0-Month Median PFS In 2L Patients With PI3Kα-Mutated, HR+/HER2- Metastatic Breast Cancer

Press Releases

Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering

Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering

Basel Medical Group Ltd Announces Exercise of Overallotment Option

Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

Basel Medical Group Ltd Kicks Off US$ 1.0 Billion Bitcoin (BTC) Acquisition Strategy Move

Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities

Basel Medical Group Ltd Enters into US$ 1.0 Billion Bitcoin (BTC) Purchase Agreement

Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility

The CHIPS Act and Peraso Inc. (NASDAQ: PRSO): Advancing Semiconductor Innovation and National Security – More Stocks Inside

BLRX

BMGL

BSLK

PRSO

SNYR

TIRX

VIVK

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Basel Medical Group

Basel Medical Group (BMGL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL